Røssevold AH, Andresen NK, Bjerre CA, Gilje B, Jakobsen EH, Raj SX, Falk RS, Russnes HG, Jahr T, Mathiesen RR, Lømo J, Garred Ø, Chauhan SK, Lereim RR, Dunn C, Naume B, Kyte JA(2022) Atezolizumab plus anthracycline-based chemotherapy in metastatic triple-negative breast cancer: the randomized, double-blind phase 2b ALICE trial Nat Med, 28(12), 2573-2583 DOI 10.1038/s41591-022-02126-1, PubMed 36482103
Dorraji E, Borgen E, Segura-Peña D, Rawat P, Smorodina E, Dunn C, Greiff V, Sekulić N, Russnes H, Kyte JA(2022) Development of a High-Affinity Antibody against the Tumor-Specific and Hyperactive 611-p95HER2 Isoform Cancers (Basel), 14(19) DOI 10.3390/cancers14194859, PubMed 36230782
Aamdal E, Skovlund E, Jacobsen KD, Straume O, Kersten C, Herlofsen O, Karlsen J, Hussain I, Amundsen A, Dalhaug A, Nyakas M, Hagene KT, Holmsen K, Aamdal S, Kaasa S, Guren TK, Kyte JA(2022) Health-related quality of life in patients with advanced melanoma treated with ipilimumab: prognostic implications and changes during treatment ESMO Open, 7(5), 100588 DOI 10.1016/j.esmoop.2022.100588, PubMed 36116420
